Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
2.
Blood Transfus ; 7(2): 127-31, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19503634

RESUMEN

BACKGROUND: Since 1999, in Mexico we have been using a regimen to conduct allografts that involves non-myeloablative conditioning and peripheral blood stem cells (PBSC) and have introduced some changes with the main goal of decreasing the cost of the procedure. MATERIALS AND METHODS: We analysed the salient apheresis features of a group of 175 allogeneic peripheral blood stem cell transplants conducted in two institutions in a 7-year period. The grafts were conducted using the "Mexican" non-myelo ablative conditioning regimen employing oral busulphan, i.v. cyclophosphamide and i.v. fludarabine. In all instances, the apheresis machine employed was the Baxter CS3000 Plus and donors were mobilised with filgrastim. The apheresis procedures were performed on days 0, +1 and +2, the end-point of collection being 5,000 mL of blood/m2 in each procedure. Three apheresis sessions were planned but the number was adjusted according to the cell yield. RESULTS: The final number of allografted CD34 cells ranged between 0.5 and 25.4 x 10(6)/Kg of the recipient's body weight (median, 5.2 x 10(6)/Kg). One to three apheresis procedures were needed to obtain a product containing more than 0.5 x 10(6) CD34 cells/Kg of the recipient, the median being two procedures; in 72 cases (41%) a single apheresis procedure was sufficient to obtain the target number of CD34 cells. The volumes of apheresis ranged between 50 and 600 mL (median, 400 mL). CONCLUSIONS: Since the median cost of each apheresis procedure is 900 USD, the fact that two apheresis procedures was spared in 72 cases and one apheresis was spared in another 65 cases, led to a total saving of approximately 188,100 USD. It can be concluded that, in many cases, allogeneic transplants can be completed with a single apheresis session and that there are considerable financial benefits from this practice.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Eliminación de Componentes Sanguíneos/métodos , Donantes de Sangre , Ablación por Catéter , Neoplasias Hematológicas/terapia , Anemia Aplásica/terapia , Eliminación de Componentes Sanguíneos/economía , Busulfano/administración & dosificación , Análisis Costo-Beneficio , Ciclofosfamida/administración & dosificación , Filgrastim , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , Neoplasias Hematológicas/economía , Neoplasias Hematológicas/mortalidad , Trasplante de Células Madre Hematopoyéticas/métodos , Humanos , Leucemia Mielógena Crónica BCR-ABL Positiva/terapia , México , Leucemia-Linfoma Linfoblástico de Células Precursoras/terapia , Proteínas Recombinantes , Estudios Retrospectivos , Análisis de Supervivencia , Acondicionamiento Pretrasplante , Trasplante Homólogo/métodos , Vidarabina/administración & dosificación , Vidarabina/análogos & derivados
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA